User login
Key clinical point: A regimen consisting of docetaxel and capecitabine (TX) followed by cyclophosphamide, epirubicin, and capecitabine (CEX) vs. only docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (T-CEF) prolonged recurrence-free survival (RFS) in patients with non- BRCA1-like early triple-negative breast cancer (TNBC).
Major finding: Overall, patients assigned to TX-CEX vs. T-CEF arms had higher RFS (hazard ratio [HR] 0.39; P = .01), with the capecitabine-containing chemotherapy being significantly more effective than conventional chemotherapy in patients with non-BRCA1-like tumor (HR 0.23; P < .01) but not in patients with BRCA1-like tumor (HR 0.66; P = .42).
Study details: Findings are from the open-label, phase 3 FinXX study including 202 patients with early TNBC who were randomly assigned to TX-CEX or T-CEF arms. BRCA1-like status was obtained for 129 patients.
Disclosures: This work was supported by the Dutch Cancer Society. The authors declared serving as board members and employees or receiving fees, grants, nonfinancial, and research support from several sources.
Source: de Boo LW et al. Br J Cancer. 2022 (Feb 5). Doi: 10.1038/s41416-022-01711-y.
Key clinical point: A regimen consisting of docetaxel and capecitabine (TX) followed by cyclophosphamide, epirubicin, and capecitabine (CEX) vs. only docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (T-CEF) prolonged recurrence-free survival (RFS) in patients with non- BRCA1-like early triple-negative breast cancer (TNBC).
Major finding: Overall, patients assigned to TX-CEX vs. T-CEF arms had higher RFS (hazard ratio [HR] 0.39; P = .01), with the capecitabine-containing chemotherapy being significantly more effective than conventional chemotherapy in patients with non-BRCA1-like tumor (HR 0.23; P < .01) but not in patients with BRCA1-like tumor (HR 0.66; P = .42).
Study details: Findings are from the open-label, phase 3 FinXX study including 202 patients with early TNBC who were randomly assigned to TX-CEX or T-CEF arms. BRCA1-like status was obtained for 129 patients.
Disclosures: This work was supported by the Dutch Cancer Society. The authors declared serving as board members and employees or receiving fees, grants, nonfinancial, and research support from several sources.
Source: de Boo LW et al. Br J Cancer. 2022 (Feb 5). Doi: 10.1038/s41416-022-01711-y.
Key clinical point: A regimen consisting of docetaxel and capecitabine (TX) followed by cyclophosphamide, epirubicin, and capecitabine (CEX) vs. only docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (T-CEF) prolonged recurrence-free survival (RFS) in patients with non- BRCA1-like early triple-negative breast cancer (TNBC).
Major finding: Overall, patients assigned to TX-CEX vs. T-CEF arms had higher RFS (hazard ratio [HR] 0.39; P = .01), with the capecitabine-containing chemotherapy being significantly more effective than conventional chemotherapy in patients with non-BRCA1-like tumor (HR 0.23; P < .01) but not in patients with BRCA1-like tumor (HR 0.66; P = .42).
Study details: Findings are from the open-label, phase 3 FinXX study including 202 patients with early TNBC who were randomly assigned to TX-CEX or T-CEF arms. BRCA1-like status was obtained for 129 patients.
Disclosures: This work was supported by the Dutch Cancer Society. The authors declared serving as board members and employees or receiving fees, grants, nonfinancial, and research support from several sources.
Source: de Boo LW et al. Br J Cancer. 2022 (Feb 5). Doi: 10.1038/s41416-022-01711-y.